-
Ice-cool Rybakina beats Sabalenka in tense Australian Open final
-
Pakistan attacks kill 15, dozens of militants dead: official
-
Ten security officials, 37 militants killed in SW Pakistan attacks: official
-
Epstein survivors say abusers 'remain hidden' after latest files release
-
'Full respect' for Djokovic but Nadal tips Alcaraz for Melbourne title
-
Wollaston goes back-to-back in the Cadel Evans road race
-
Women in ties return as feminism faces pushback
-
Ship ahoy! Prague's homeless find safe haven on river boat
-
Britain's Starmer ends China trip aimed at reset despite Trump warning
-
Carlos Alcaraz: rare tennis talent with shades of Federer
-
Novak Djokovic: divisive tennis great on brink of history
-
History beckons for Djokovic and Alcaraz in Australian Open final
-
Harrison, Skupski win Australian Open men's doubles title
-
Epstein offered ex-prince Andrew meeting with Russian woman: files
-
Jokic scores 31 to propel Nuggets over Clippers in injury return
-
Montreal studio rises from dark basement office to 'Stranger Things'
-
US government shuts down but quick resolution expected
-
Mertens and Zhang win Australian Open women's doubles title
-
Venezuelan interim president announces mass amnesty push
-
China factory activity loses steam in January
-
Melania Trump's atypical, divisive doc opens in theatres
-
Bad Bunny set for historic one-two punch at Grammys, Super Bowl
-
Five things to watch for on Grammys night Sunday
-
Venezuelan interim president proposes mass amnesty law
-
Rose stretches lead at Torrey Pines as Koepka makes cut
-
Online foes Trump, Petro set for White House face-to-face
-
Seattle Seahawks deny plans for post-Super Bowl sale
-
US Senate passes deal expected to shorten shutdown
-
'Misrepresent reality': AI-altered shooting image surfaces in US Senate
-
Thousands rally in Minneapolis as immigration anger boils
-
US judge blocks death penalty for alleged health CEO killer Mangione
-
Lens win to reclaim top spot in Ligue 1 from PSG
-
Gold, silver prices tumble as investors soothed by Trump Fed pick
-
Ko, Woad share lead at LPGA season opener
-
US Senate votes on funding deal - but shutdown still imminent
-
US charges prominent journalist after Minneapolis protest coverage
-
Trump expects Iran to seek deal to avoid US strikes
-
US Justice Dept releases documents, images, videos from Epstein files
-
Guterres warns UN risks 'imminent financial collapse'
-
NASA delays Moon mission over frigid weather
-
First competitors settle into Milan's Olympic village
-
Fela Kuti: first African to get Grammys Lifetime Achievement Award
-
Cubans queue for fuel as Trump issues oil ultimatum
-
'Schitt's Creek' star Catherine O'Hara dead at 71
-
Curran hat-trick seals 11 run DLS win for England over Sri Lanka
-
Cubans queue for fuel as Trump issues energy ultimatum
-
France rescues over 6,000 UK-bound Channel migrants in 2025
-
Surprise appointment Riera named Frankfurt coach
-
Maersk to take over Panama Canal port operations from HK firm
-
US arrests prominent journalist after Minneapolis protest coverage
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced that on January 8, 2026, the Compensation Committee of Revelation's Board of Directors approved an inducement grant consisting of 90,000 restricted stock units ("RSUs") covering 90,000 shares of the Company's common stock to a new non-executive employee. The RSUs were granted outside of the Company's stockholder-approved equity incentive plan. The award was granted as an inducement material to the employee's acceptance of employment with Revelation in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over two years in equal quarterly installments, beginning on the first quarterly vesting date following the employee's new hire date, subject to the employee's continued service with the Company through the vesting dates.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.
For more information on Revelation, please visit www.RevBiosciences.com.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: [email protected]
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
D.Lopez--AT